HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | 5-HT ↓ ↑ | 5-HT1 ↓ ↑ | 5-HT2 ↓ ↑ | 5-HT3 ↓ ↑ | 5-HT5 ↓ ↑ | 5-HT6 ↓ ↑ | 5-HT7 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Desvenlafaxine |
++
5-HT, Ki: 40.2 nM |
98% | |||||||||||||||||
| Lamotrigine |
+
5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM |
98% | |||||||||||||||||
| Venlafaxine | ✔ | 99% | |||||||||||||||||
| Fluvoxamine maleate | ✔ | 99% | |||||||||||||||||
| Iloperidone | ✔ | 99% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Atomoxetine HCI |
+
5-HT, Ki: 77 nM |
98% | |||||||||||||||||
| Dapoxetine HCl | ✔ | 97% | |||||||||||||||||
| Trazodone | ✔ | 98+% | |||||||||||||||||
| Clomipramine HCl | ✔ | 98% | |||||||||||||||||
| Mirtazapine | ✔ | 99+% | |||||||||||||||||
| Escitalopram oxalate |
+++
5-HT, Ki: 0.89 nM |
97% | |||||||||||||||||
| Duloxetine | ✔ | 97% | |||||||||||||||||
| Sertraline HCl |
++
5-HT, Ki: 13 nM |
98% | |||||||||||||||||
| Citalopram HBr |
+++
serotonin reuptake, IC50: 1.8 nM |
98% | |||||||||||||||||
| Latrepirdine 2HCl | ✔ | GluR | 99% | ||||||||||||||||
| Fluoxetine HCl | ✔ | 99.5% | |||||||||||||||||
| Paroxetine HCl | ✔ | AChR | 99% | ||||||||||||||||
| BMY 7378 |
++
5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4 |
+
5-HT2, pIC50: 5.5 |
97% | ||||||||||||||||
| Flibanserin |
+++
5-HT1A, Ki: 1 nM |
+
5-HT2A, Ki: 49 nM |
95% | ||||||||||||||||
| LY310762 |
+
5-HT1D, Ki: 249 nM |
99%+ | |||||||||||||||||
| Cyclobenzaprine HCI | ✔ | 99% | |||||||||||||||||
| Blonanserin |
+++
5-HT2, Ki: 3.98 nM |
99% | |||||||||||||||||
| Cyproheptadine HCl |
++++
5-HT2, IC50: 0.6 nM |
99+% | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Pimavanserin hemitartrate |
+++
5-HT2A, pIC50: 8.7 |
99% | |||||||||||||||||
| Ketanserin |
+++
5-HT2C (Human), Ki: 2.5 nM 5-HT2C (Rat), Ki: 50 nM |
99%+ | |||||||||||||||||
| Loxapine succinate |
++
5-HT2 (bovine), Ki: 6.6 nM 5-HT2 (human), Ki: 6.8 nM |
98% | |||||||||||||||||
| Agomelatine | ✔ | 98% | |||||||||||||||||
| Clozapine | ✔ | 98% | |||||||||||||||||
| Amitriptyline |
+
5-HT2, Ki: 235 nM |
SERT | 99% | ||||||||||||||||
| PRX-08066 maleate |
+++
5-HT2B, IC50: 3.4 nM |
98+% | |||||||||||||||||
| RS-127445 |
++++
5-HT2B, pKi: 9.5 5-HT2B, pIC50: 10.4 |
99%+ | |||||||||||||||||
| Sarpogrelate HCl |
++++
5-HT2C, Kd: 1.1 nM 5-HT2A, Kd: 2.1 nM |
98% | |||||||||||||||||
| Tropisetron | ✔ | 99% | |||||||||||||||||
| Ramosetron HCl |
++++
5-HT3 receptor, Ki: 0.091 nM |
98% | |||||||||||||||||
| Ondansetron | ✔ | 99% | |||||||||||||||||
| Granisetron | ✔ | 98% | |||||||||||||||||
| Alosetron HCl | ✔ | 98% | |||||||||||||||||
| Ondansetron HCl dihydrate | ✔ | 98% | |||||||||||||||||
| VUF10166 |
++++
5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM |
99%+ | |||||||||||||||||
| Azasetron HCl |
++++
5-HT3, IC50: 0.33 nM |
99% | |||||||||||||||||
| Asenapine maleate |
+++
5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6 |
++++
5-HT2A, pKi: 9.75 5-HT2C, pKi: 10.46 |
+++
5-HT5A, pKi: 8.84 |
++++
5-HT6, pKi: 9.6 |
++++
5-HT7, pKi: 9.94 |
97% | |||||||||||||
| Risperidone |
++
5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM |
++++
5-HT2A, Ki: 61.9 nM 5-HT2C, Ki: 12 nM |
+
5-HT5A, Ki: 206 nM |
++
5-HT7, Ki: 6.6 nM |
98% | ||||||||||||||
| SB 271046 HCl |
+++
5-HT6, pKi: 8.92 |
99%+ | |||||||||||||||||
| Intepirdine |
++++
5-HT6, pKi: 9.63 |
99%+ | |||||||||||||||||
| SB-269970 HCl |
++
5-HT7, pKi: 8.3 |
98+% | |||||||||||||||||
| BRL 15572 |
++
5-HT1B, pKi: 6.1 5-HT1D, pKi: 6 |
++
5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2 |
+
5-HT6, pKi: 5.9 |
+
5-HT7, pKi: 6.3 |
95% | ||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Clozapine N-oxide, a primary metabolite of Clozapine, serves as an agonist for human muscarinic designer receptors (DREADDs), effectively activating DREADD receptors hM3Dq and hM4Di, and is capable of crossing the blood-brain barrier[1].[2].[3].[4]. Clozapine itself is known as a powerful antagonist of dopamine and a selective agonist for the muscarinic M4 receptor, with an EC50 value of 11 nM[5].[6]. |
| 体内研究 | After a single intraperitoneal injection of 1 mg/kg Clozapine N-oxide into mice, peak plasma levels of CNO are reached at 15 minutes, declining significantly after 2 hours. Despite this short plasma half-life in mice, the physiological and behavioral effects described following acute treatment in DREADD-expressing experimental animals typically extend much longer, between 6-10 hours[1]. |
| 体外研究 | Clozapine N-oxide (CNO) can bind to non-DREADD receptors at concentrations necessary for DREADD activation and can undergo reverse metabolism back to its parent compound clozapine, an atypical antipsychotic with a wide range of pharmacological targets and effects[2]. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Shank2/C0//C0 mouse model | Subcutaneous injection | 5 mg/kg | Once daily for 5 days | Selective enhancement of MPOA activity by DREADD technology re-established social bonding behavior in Shank2/C0//C0 mice, providing evidence that the identified circuit might be crucial for explaining how social deficits in ASD can arise. | EMBO J. 2021 Mar 1;40(5):e104267 |
| Mice | Spinal cord injury model | 10 mg/kg | Single administration, effects evaluated at 1 h and 24 h post-administration | To assess the impact of inhibiting neuronal activity of transplanted hM4Di-NS/PCs on locomotor function in mice, results showed that CNO administration significantly reduced locomotor function in the transplanted group. | Stem Cell Reports. 2022 Jan 11;17(1):127-142 | |
| Rats | Parkinson's disease rat model | Intraperitoneal injection | 1 mg/kg | Single injection, lasting up to 10 hours | DREADD activation of PPN cholinergic neurons significantly reversed motor deficits and restored striatal dopamine signaling in Parkinsonian rats. | Neurotherapeutics. 2020 Jul;17(3):1120-1141 |
| C57BL/6J mice | Binge-like ethanol drinking model | Intraperitoneal injection | 1 mg/kg, 2 mg/kg | Administered 15-30 minutes prior to each DID session, lasting for 7 days | Activation of CeA to NAc core projection neurons reduced binge-like ethanol drinking, and this effect was dependent on CRF signaling. | Neuropharmacology. 2022 Feb 1;203:108874 |
| Mice | Transgenic mice | Injection | 5 μg/g | Single injection, 30 minutes before behavioral experiments | Activation of CEl CRH+ cells to increase passive behaviors | Mol Psychiatry. 2020 Feb;25(2):428-441 |
| Mice | Gi-DREADD expressing mice | Intraperitoneal injection | 5 mg/kg | Single administration | CNO targets Gi-DREDD to reduce endogenous NE release and subsequently increase microglial process surveillance. | Nat Neurosci. 2019 Nov;22(11):1771-1781 |
| Mice | AgRP-Sirt1KO mice | Intraperitoneal injection | 10 mg/kg | Once daily for 11-15 days | Clozapine prevented the loss of superficial layer PL mPFC neurons in AgRP-Sirt1KO mice and restored normal PPI response. | Mol Psychiatry. 2022 Oct;27(10):3951-3960 |
| Mice | CRF-Cre mice | Intraperitoneal injection | 3 mg/kg | Single administration | To investigate the effect of CNO on Gi-DREADD activation in CRF-Cre mice, results showed that CNO significantly suppressed binge alcohol drinking and reduced anxiety-like behavior. | Nat Neurosci. 2015 Apr;18(4):545-52. |
| Rats | TTX model | Intraperitoneal injection | 1 mg/kg | Single dose | Activate DREADD receptors, increase spasm counts and clustering | Ann Neurol. 2021 Feb;89(2):226-241 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.92mL 0.58mL 0.29mL |
14.58mL 2.92mL 1.46mL |
29.17mL 5.83mL 2.92mL |
|
| CAS号 | 34233-69-7 |
| 分子式 | C18H19ClN4O |
| 分子量 | 342.82 |
| SMILES Code | [O-][N+]1(C)CCN(C2=NC3=CC(Cl)=CC=C3NC4=CC=CC=C42)CC1 |
| MDL No. | MFCD00210190 |
| 别名 | 氯氮平N-氧化 ;CNO |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(306.28 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 1 mg/mL(2.92 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1